MBOT - Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical Regulatory and Commercial Activities | Benzinga
BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring of Dr. Diaz-Cartelle, a U.S.-based physician, coincides with the transition of the Company focusing mainly on research and development in Israel to the Company increasing its U.S.-based activities, which includes its planned clinical trials for the LIBERTY® Endovascular Robotic Surgical System in the U.S., the regulatory process with the FDA and establishing the commercial foundations to enter the U.S market.
Dr. Diaz-Cartelle brings to Microbot a wealth of experience in the endovascular and interventional space, along with an impressive track record in clinical research. Before joining the Company, Dr. Diaz-Cartelle served for 14 years as the Senior Medical Director for the Peripheral Interventional Division (Endovascular and Interventional Oncology) at Boston Scientific Corporation. In this role, he played a pivotal part in the development of global clinical strategy and study oversight, supporting commercial activities and future pipeline development. Most recently he served as the Executive Medical Director at Haemonetics Corporation, where he advised the company on new investments in the cardiovascular space, among other responsibilities. Before joining the corporate life, he worked at NYU as a research scientist.
"We are fortunate to have Dr. Diaz-Cartelle join our team, especially with his extensive experience in the endovascular and interventional space. Dr. Diaz-Cartelle's appointment is a testament to our commitment to excellence in our transition to the clinical and regulatory phase, especially as we ...